scholarly journals Highly selective and rapidly activatable fluorogenic Thrombin sensors and application in human lung tissue

2017 ◽  
Vol 15 (20) ◽  
pp. 4344-4350 ◽  
Author(s):  
Alicia Megia-Fernandez ◽  
Bethany Mills ◽  
Chesney Michels ◽  
Sunay V. Chankeshwara ◽  
Kevin Dhaliwal ◽  
...  

A fast and selective fluorogenic probe for Thrombin is reported and applied in ex vivo fibrotic human lung tissue.


2015 ◽  
Vol 6 (8) ◽  
pp. 4946-4953 ◽  
Author(s):  
Tashfeen Aslam ◽  
Amy Miele ◽  
Sunay V. Chankeshwara ◽  
Alicia Megia-Fernandez ◽  
Chesney Michels ◽  
...  

A fluorogenic probe provides real-time measurement of lysyl oxidase activity in ex vivo asinine and human lung tissue.



Gene Therapy ◽  
2000 ◽  
Vol 7 (8) ◽  
pp. 675-678 ◽  
Author(s):  
S McBride ◽  
D Rannie ◽  
D J Harrison


1998 ◽  
Vol 47 (12) ◽  
pp. 501-505 ◽  
Author(s):  
D. Nissen ◽  
L. J. Petersen ◽  
H. Nolte ◽  
H. Permin ◽  
N. Melchior ◽  
...  




Author(s):  
Laura Mueller ◽  
Nadine Kraemer ◽  
Peter Braubach ◽  
Danny Jonigk ◽  
Hans-Gerd Fieguth ◽  
...  


2016 ◽  
Vol 84 (5) ◽  
pp. 1438-1445 ◽  
Author(s):  
Joseph G. Graham ◽  
Caylin G. Winchell ◽  
Richard C. Kurten ◽  
Daniel E. Voth

Coxiella burnetiiis an intracellular bacterial pathogen that causes human Q fever, an acute debilitating flu-like illness that can also present as chronic endocarditis. Disease typically occurs following inhalation of contaminated aerosols, resulting in an initial pulmonary infection. In human cells,C. burnetiigenerates a replication niche termed the parasitophorous vacuole (PV) by directing fusion with autophagosomes and lysosomes.C. burnetiirequires this lysosomal environment for replication and uses a Dot/Icm type IV secretion system to generate the large PV. However, we do not understand howC. burnetiievades the intracellular immune surveillance that triggers an inflammatory response. We recently characterized human alveolar macrophage (hAM) infectionin vitroand found that avirulentC. burnetiitriggers sustained interleukin-1β (IL-1β) production. Here, we evaluated infection ofex vivohuman lung tissue, defining a valuable approach for characterizingC. burnetiiinteractions with a human host. Within whole lung tissue,C. burnetiipreferentially replicated in hAMs. Additionally, IL-1β production correlated with formation of an apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC)-dependent inflammasome in response to infection. We also assessed potential activation of a human-specific noncanonical inflammasome and found that caspase-4 and caspase-5 are processed during infection. Interestingly, although inflammasome activation is closely linked to pyroptosis, lytic cell death did not occur followingC. burnetii-triggered inflammasome activation, indicating an atypical response after intracellular detection. Together, these studies provide a novel platform for studying the human innate immune response toC. burnetii.



Author(s):  
Bethany Mills ◽  
Ahsan R. Akram ◽  
Emma Scholefield ◽  
Mark Bradley ◽  
Kevin Dhaliwal


2020 ◽  
Vol 17 (6) ◽  
pp. 688-698
Author(s):  
Binaya KC ◽  
Parth Sarathi Mahapatra ◽  
Dhruma Thakker ◽  
Amanda P. Henry ◽  
Charlotte K. Billington ◽  
...  




2009 ◽  
Vol 53 (9) ◽  
pp. 3935-3941 ◽  
Author(s):  
Renee W. Y. Chan ◽  
Michael C. W. Chan ◽  
Adam C. N. Wong ◽  
Rositsa Karamanska ◽  
Anne Dell ◽  
...  

ABSTRACT DAS181 is a novel candidate therapeutic agent against influenza virus which functions via the mechanism of removing the virus receptor, sialic acid (Sia), from the adjacent glycan structures. DAS181 and its analogues have previously been shown to be potently active against multiple strains of seasonal and avian influenza virus strains in several experimental models, including cell lines, mice, and ferrets. Here we demonstrate that DAS181 treatment leads to desialylation of both α2-6-linked and α2-3-linked Sia in ex vivo human lung tissue culture and primary pneumocytes. DAS181 treatment also effectively protects human lung tissue and pneumocytes against the highly pathogenic avian influenza virus H5N1 (A/Vietnam/3046/2004). Two doses of DAS181 treatment given 12 h apart were sufficient to block H5N1 infection in the ex vivo lung tissue culture. These findings support the potential value of DAS181 as a broad-spectrum therapeutic agent against influenza viruses, especially H5N1.



Sign in / Sign up

Export Citation Format

Share Document